VantroMarket Overview
← All markets
Health Market Overview

Austria

Last updated: November 2026
Regulatory Body
Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES) - Austrian Agency for Health and Food Safety, acting under the authority of the Federal Ministry of Social Affairs, Health, Care and Consumer Protection (Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz, BMSGPK)
Typical Timeline
30-210 days depending on product category and procedure type (national, MRP, DCP, or centralised via EMA)
Regulatory Overview

Austria's primary regulatory authority for health products is AGES (Österreichische Agentur für Gesundheit und Ernährungssicherheit), which operates under the oversight of the BMSGPK. Pharmaceuticals are governed by the Arzneimittelgesetz (AMG, Medicinal Products Act), medical devices fall under EU Regulations MDR 2017/745 and IVDR 2017/746 as directly applicable law, and digital health solutions may be subject to both medical device classification rules and the national Digital Healthcare Act framework. Austria participates fully in the European Medicines Agency (EMA) centralised procedure for eligible medicinal products, and also uses the Mutual Recognition Procedure (MRP) and Decentralised Procedure (DCP) for national and cross-border approvals. AGES serves as a Reference Member State or Concerned Member State in these EU procedures and conducts standalone national assessments where applicable.

For pharmaceutical submissions, Austria follows the Common Technical Document (CTD) format in line with ICH guidelines and EU requirements, with eCTD submissions mandatory for most applications. Applicants based outside the European Economic Area must appoint a local EU-based Marketing Authorisation Holder or regulatory representative. Medical devices require CE marking under MDR/IVDR, with registration in the European EUDAMED database, and no additional national pre-market approval is required beyond CE certification. Recent reforms include Austria's implementation of the EU Joint Clinical Assessment (JCA) framework under HTA Regulation (EU) 2021/2282, which became applicable from January 2025 for oncology and advanced therapy medicinal products, aligning national health technology assessments with EU-level scientific conclusions. The national HTA body, the HVB (Hauptverband der österreichischen Sozialversicherungsträger, now operating under Dachverband), coordinates reimbursement evaluations following regulatory approval.

Procurement Overview

Austria operates a federal social health insurance system administered by the Österreichische Gesundheitskasse (OeGK) and several occupational and regional health insurance funds, all coordinated under the umbrella of the Dachverband der Sozialversicherungsträger. Public procurement of pharmaceuticals is primarily driven by the Heilmittelverzeichnis (HMV), the national reimbursement list, with pricing and reimbursement decisions negotiated between manufacturers and the Dachverband. Hospital procurement is largely decentralised to the nine federal states (Bundesländer), each managing its own hospital fund (Landesgesundheitsfonds) and conducting independent or consortium-based tender processes for medicines, medical devices, and diagnostics. The Bundesbeschaffung GmbH (BBG), Austria's federal procurement agency, coordinates framework agreements for certain product categories used by public hospitals and federal institutions, enabling volume-based pricing advantages across participating entities.

The private sector in Austria accounts for a meaningful share of health product uptake, particularly for over-the-counter products, premium medical devices, and digital health applications distributed through private clinics, pharmacies, and direct-to-consumer channels. Austria is a high-income EU member state and therefore does not typically rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, which are oriented toward low- and middle-income country markets. However, Austrian institutions and manufacturers may engage with these mechanisms through export or development cooperation activities. Austria does not impose formal local manufacturing preference policies in public procurement, as EU public procurement directives (2014/24/EU and 2014/25/EU) prohibit discriminatory national preferences among EU member states. Nonetheless, supply chain resilience initiatives at the EU level, including the Critical Medicines Act discussions and IPCEI Health projects, are increasingly influencing strategic procurement planning for essential medicines and health technologies within Austria.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Austria →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.